Humanigen Inc (OTCQB:HGEN) revealed on Tuesday that the first patient had been infused in its Phase 1/2 clinical trial of a treatment for those with relapsed or refractory Large B-cell Lymphoma.
This so-called ZUMA-19 study is being conducted in collaboration with Kite, which is a Gilead Sciences (NASDAQ:GILD) company.
READ: Humanigen says lenzilumab drug delivers better recovery time for coronavirus-associated pneumonia in cross-trial analysis
"We are excited to see this clinical collaboration move forward as we seek to understand the potential benefit of lenzilumab being administered with CAR T therapy in patients with relapsed or refractory large B-cell lymphoma," Cameron Durrant, the chief executive officer of Humanigen said in a statement.
The trial is a multi-center open-label study involving 36 participants.
Humanigen, a clinical-stage pharma group, and Kite are evaluating Humanigen's therapy lenzilumab in combination with Yescarta (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma.
The group is also currently focused on preventing or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of the coronavirus (COVID-19 infection.
Contact the author at [email protected]